TY - JOUR
T1 - Endotrophin Levels Are Associated with Allograft Outcomes in Kidney Transplant Recipients
AU - Sparding, Nadja
AU - Genovese, Federica
AU - Rasmussen, Daniel Guldager Kring
AU - Karsdal, Morten A
AU - Krogstrup, Nicoline V
AU - Nielsen, Marie Bodilsen
AU - Hornum, Mads
AU - Nagarajah, Subagini
AU - Birn, Henrik
AU - The Context Study Group, null
AU - Jespersen, Bente
AU - Tepel, Martin
AU - Nørregaard, Rikke
PY - 2023/5/5
Y1 - 2023/5/5
N2 - Early prediction of kidney graft function may assist clinical management, and for this, reliable non-invasive biomarkers are needed. We evaluated endotrophin (ETP), a novel non-invasive biomarker of collagen type VI formation, as a prognostic marker in kidney transplant recipients. ETP levels were measured with the PRO-C6 ELISA in the plasma (P-ETP) of 218 and urine (U-ETP/Cr) of 172 kidney transplant recipients, one (D1) and five (D5) days, as well as three (M3) and twelve (M12) months, after transplantation. P-ETP and U-ETP/Cr at D1 (P-ETP AUC = 0.86, p < 0.0001; U-ETP/Cr AUC = 0.70, p = 0.0002) were independent markers of delayed graft function (DGF) and P-ETP at D1 had an odds ratio of 6.3 (p < 0.0001) for DGF when adjusted for plasma creatinine. The results for P-ETP at D1 were confirmed in a validation cohort of 146 transplant recipients (AUC = 0.92, p < 0.0001). U-ETP/Cr at M3 was negatively associated with kidney graft function at M12 (p = 0.007). This study suggests that ETP at D1 can identify patients at risk of delayed graft function and that U-ETP/Cr at M3 can predict the future status of the allograft. Thus, measuring collagen type VI formation could aid in predicting graft function in kidney transplant recipients.
AB - Early prediction of kidney graft function may assist clinical management, and for this, reliable non-invasive biomarkers are needed. We evaluated endotrophin (ETP), a novel non-invasive biomarker of collagen type VI formation, as a prognostic marker in kidney transplant recipients. ETP levels were measured with the PRO-C6 ELISA in the plasma (P-ETP) of 218 and urine (U-ETP/Cr) of 172 kidney transplant recipients, one (D1) and five (D5) days, as well as three (M3) and twelve (M12) months, after transplantation. P-ETP and U-ETP/Cr at D1 (P-ETP AUC = 0.86, p < 0.0001; U-ETP/Cr AUC = 0.70, p = 0.0002) were independent markers of delayed graft function (DGF) and P-ETP at D1 had an odds ratio of 6.3 (p < 0.0001) for DGF when adjusted for plasma creatinine. The results for P-ETP at D1 were confirmed in a validation cohort of 146 transplant recipients (AUC = 0.92, p < 0.0001). U-ETP/Cr at M3 was negatively associated with kidney graft function at M12 (p = 0.007). This study suggests that ETP at D1 can identify patients at risk of delayed graft function and that U-ETP/Cr at M3 can predict the future status of the allograft. Thus, measuring collagen type VI formation could aid in predicting graft function in kidney transplant recipients.
KW - Humans
KW - Kidney Transplantation/adverse effects
KW - Collagen Type VI
KW - Delayed Graft Function/etiology
KW - Transplant Recipients
KW - Allografts
KW - Risk Factors
UR - http://www.scopus.com/inward/record.url?scp=85160374431&partnerID=8YFLogxK
U2 - 10.3390/biom13050792
DO - 10.3390/biom13050792
M3 - Journal article
C2 - 37238662
SN - 2218-273X
VL - 13
JO - Biomolecules
JF - Biomolecules
IS - 5
M1 - 792
ER -